AcrySof IQ Vivity IOL | Simplifying Presbyopia Correction | MyAlcon AU and NZ
Home pageMyAlcon Professional Logo
Online Store
MyAlcon for Consumers

MyAlcon | Australia and New Zealand

This page is available in English. Select below for other countries.

Select another country

AcrySof IQ Vivity® IOL

Simplifying Presbyopia
Correction1-8

 

The First and Only presbyopia-correcting IOL
with wavefront-shaping technology and a clinically
proven low rate of visual disturbances1-4

AcrySof IQ Vivity® IOL

Simplifying Presbyopia Correction1-8

 

The First and Only presbyopia-correcting IOL with wavefront-shaping technology and a clinically proven low rate of visual disturbances1-4

 


Results from 2 Large Independent Trials:

 

AcrySof IQ Vivity® IOL Delivers Excellent Distance, Intermediate and Functional Near Vision3,4

Blue icon of a car on a pale blue background.
Blue icon of a car on a pale blue background.

20/20

 

Binocular Mean 
Uncorrected Distance 
Visual Acuity (4 m)*

 

DISTANCE

Blue icon showing an open laptop on a pale blue background.
Blue icon showing an open laptop on a pale blue background.

Better Than 20/25

 

Binocular Mean 
Uncorrected Intermediate 
Visual Acuity (66 cm)*

 

INTERMEDIATE

Blue icon showing a hand holding a cell phone on a pale blue background.
Blue icon showing a hand holding a cell phone on a pale blue background.

20/32

 

Binocular Mean 
Uncorrected Near 
Visual Acuity (40 cm)*

 

NEAR

*Binocular uncorrected visual acuity results from a prospective, randomised, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months’ follow-up.

In All Light Conditions, AcrySof IQ Vivity® IOL Patients Reported Monofocal-Quality Distance With Excellent Intermediate and Functional Near Vision4

 

 

Percent of Patients Reporting Good or Very Good Vision Without Spectacles at 6 Months in Validated IOLSAT Questionnaire4*† 

Bar graph showing the percent of patients reporting good or very good vision at 6 months without spectacles in bright light, where the best outcome would be 100%. 106 patients were implanted with Vivity® IOL, and 113 patients were implanted with AcrySof® IQ monofocal IOL. The graph displays that with the Vivity® IOL, 94% of patients at far, 92% of patients at arm’s length, and 57% of patients up-close reported good or very good vision. With the AcrySof® IQ monofocal IOL, 92% of patients at far away, 63% of patients at arm’s length and 25% of patients up close reported good or very good vision. Bar graph showing the percent of patients reporting good or very good vision at 6 months without spectacles in dim light, where the best outcome would be 100%. 106 patients were implanted with Vivity® IOL, and 113 patients were implanted with AcrySof® IQ monofocal IOL. The graph displays that with the Vivity® IOL, 88% of patients at far, 83% of patients at arm’s length, and 38% of patients at up-close reported good or very good vision. With the AcrySof® IQ monofocal IOL, 78% of patients at far away, 51% of patients at arm’s length and 8% of patients up close reported good or very good vision.

*Patients were asked, “How well did you see without wearing eyeglasses in the past 7 days?”

†Results from a prospective, randomised, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity® Extended Vision IOL and 113 with the AcrySof® IQ IOL with 6 months follow-up.

AcrySof IQ Vivity® IOL Visual Disturbance Profile is Comparable to the AcrySof® IQ Monofocal1,3,4

 

 

The majority of AcrySof IQ Vivity® IOL patients were not bothered at all by visual disturbances.4

 

 

Degree of Bother (%)*
Bar graph reporting how bothered patients were by starbursts, halos and glare after implantation with AcrySof IQ Vivity® IOL and AcrySof® IQ monofocal IOL. 106 patients were implanted with Vivity® IOL, and 110 patients were implanted with AcrySof® IQ monofocal IOL. The graph displays that with the Vivity® IOL, 74% of Vivity® patients and 72% of monofocal patients were not bothered at all by starbursts. 83% of Vivity® patients and 89% of monofocal patients were not bothered at all by halos. 78% of Vivity® patients and 76% of monofocal patients were not bothered at all by glare. 14% of Vivity® patients and 15% of monofocal patients were bothered a little by starbursts. 12% of Vivity® patients and 6% of monofocal patients were bothered a little by halos. 11% of Vivity® patients and 10% of monofocal patients were bothered a little by glare. 9% of Vivity® patients and 11% of monofocal patients were bothered somewhat by starbursts. 3% of Vivity® patients and 5% of monofocal patients were bothered somewhat by halos. 7% of Vivity® patients and 12% of monofocal patients were bothered somewhat by glare. 1% of Vivity® patients and 2% of monofocal patients were bothered quite a bit by starbursts. 1% of Vivity® patients and 1% of monofocal patients were bothered quite a bit by halos. 4% of Vivity® patients and 3% of monofocal patients were bothered quite a bit by glare. 2% of Vivity® patients and 1% of monofocal patients were bothered very much by starbursts. 1% of Vivity® patients and 0% of monofocal patients were bothered very much by halos. 0% of Vivity® patients and 0% of monofocal patients were bothered very much by glare.

Diffractive trifocal technology IOLs can deliver reduced spectacle dependence, but it’s not for every patient. Some patients are not candidates due to low tolerance for visual disturbances or other ocular health problems.11-13

*Results from a prospective, randomised, parallel group, subject and assessor masked, multisite trial of 107 subjects bilaterally implanted with AcrySof IQ Vivity® Extended Vision IOL and 113 with AcrySof® IQ IOL with 6 months follow-up. Visual disturbances were evaluated subjectively through QUVID questionnaire. Patients were asked: “In the past 7 days, how much were you bothered with starbursts, halos, and glare?” ​

Visual Disturbance Profile: AcrySof IQ Vivity® Had an Optical Halo Comparable to a Monofocal IOL5

 

Optical Bench Halo Measurements (4.5 mm Pupil Size)

Black background with a bright light in the middle representing the optical bench halo measurement for AcrySof® IQ Monofocal IOL.
Black background with a bright light in the middle representing the optical bench halo measurement for AcrySof® IQ Monofocal IOL.

 

AcrySof® IQ
Monofocal IOL
Black background with a bright light in the middle with a slight halo around the light, representing the optical bench halo measurement for AcrySof IQ Vivity® IOL.
Black background with a bright light in the middle with a slight halo around the light, representing the optical bench halo measurement for AcrySof IQ Vivity® IOL.

 

AcrySof IQ Vivity®
IOL Wavefront-Shaping
Technology
Black background with a bright light in the middle, with a halo around the light larger than the AcrySof® IQ Monofocal and AcrySof IQ Vivity® IOLs, representing the optical bench halo measurement for TECNIS Symfony Diffractive EDF IOL
Black background with a bright light in the middle, with a halo around the light larger than the AcrySof® IQ Monofocal and AcrySof IQ Vivity® IOLs, representing the optical bench halo measurement for TECNIS Symfony Diffractive EDF IOL

 

TECNIS Symfony*
Diffractive EDoF
Black background with a bright light in the middle, showing the largest halo around the light compared to the three other images, representing the optical bench halo measurement for ZEISS AT LARA Diffractive EDF IOL.
Black background with a bright light in the middle, showing the largest halo around the light compared to the three other images, representing the optical bench halo measurement for ZEISS AT LARA Diffractive EDF IOL.

 

ZEISS AT LARA* 829 MP Diffractive EDoF

These are representative images from a benchtop study.

*Trademarks are property of their respective owners.

    Wavefront-Shaping Technology
    AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4

     

    ✓ The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2

     

    ✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the AcrySof IQ Vivity® IOL.
    Surface Transition #1
    AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4

     

    ✓ The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2

     

    ✓ Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the AcrySof IQ Vivity® IOL with white graphic lines that draw focus to the middle of the lens, highlighting the slightly elevated smooth plateau that contributes to the lens’s wavefront-shaping technology.
    Surface Transition #2
    AcrySof IQ Vivity® IOL is the First and Only presbyopia-correcting IOL that uses a next generation optical principle, called wavefront-shaping, that stretches and shifts the light1-4

     

    ✓  The AcrySof IQ Vivity® IOL uses wavefront-shaping technology, which is invisible to the naked eye, making it virtually indistinguishable from the AcrySof® IQ monofocal1,2

     

    ✓  Surface Transition #1: A slightly elevated smooth plateau (~1 µm high) that stretches the wavefront, creating a continuous focal range2

     

    ✓ Surface Transition #2: A small curvature change (across the 2.2 mm region) that shifts the wavefront to utilize all available light energy2

    Golden 3-dimensional image of the AcrySof IQ Vivity® IOL with white graphic lines that draw focus to the middle of the lens highlighting the small curvature change that contributes to the lens’s wavefront-shaping technology.

    Unique Mechanism of Action 
     

    The AcrySof IQ Vivity® IOL uses wavefront-shaping technology to deliver distance, intermediate, and functional near vision for patients, as well as a clinically proven low rate of visual disturbances.1-4


    The wavefront-shaping technology of the AcrySof IQ Vivity® IOL is called X-WAVE™ Technology and is proprietary to Alcon.


    Wavefront-shaping stretches the light. It doesn’t bend light like refraction, or split light like diffraction.


    Similar to a monofocal, Vivity® utilizes essentially all of the transmitted light energy that passes through the lens. The smooth surface transition elements on the AcrySof IQ Vivity® IOL stretch and shift the wavefront to provide a full range of vision with functional near visual acuity to help reduce spectacle dependence.1-4 

      NIGHTTIME

       

      Clinically Proven Low Rate of Visual Disturbances1-4

      Car on the road in dim lighting with phone set up on the dashboard. White text at the top left corner of this image reads “Monofocal.”
      Car on the road in dim lighting with phone set up on the dashboard. White text at the top left corner of this image reads “AcrySof IQ Vivity.”

       

       

      Vision Simulation: Night-time Activity

       

      DAYTIME

       

      AcrySof IQ Vivity® IOL Delivers Excellent Distance, Intermediate and Functional Near Vision3,4

      Slightly blurred image of a coffee shop with a view from the counter of coffee machines and other ingredients. A laptop is open on the countertop and an individual’s hand holds up a coffee mug to the right of the laptop screen. White text at the top left corner of this image reads “Monofocal.”
      Clear image of a coffee shop with a view from the counter of coffee machines and other ingredients. A laptop is open on the countertop and an individual’s hand holds up a coffee mug to the right of the laptop screen. White text at the top left corner of this image reads “AcrySof IQ Vivity.”

       

       

      Vision Simulation: Day-time Activity

       

      SMART Educator

      Surface Transition Elements Affect Light Energy Distribution*

       

      The proprietary, wavefront-shaping design creates a monofocal visual disturbance profile and a continuous range of vision for patients.1-4 With the AcrySof IQ Vivity® IOL, light spans a continuous focal range, instead of being split amongst multiple focal points.9

      A graphic illustrating the range of vision with four different IOLs. The AcrySof® IQ monofocal IOL provides distance vision. The Symfony IOL provides distance, intermediate and near vision. The AT LARA IOL provides vision at distance and two intermediate focal points. The AcrySof IQ Vivity® IOL provides a continuous range of vision from distance to functional near.

      *Simulated photopic through-focus point spread function (light intensity [energy]) – polychromatic.

      †Trademarks are the property of their respective owners.

      The Flat Defocus Curve Delivers Confidence in Hitting a Refractive Target With AcrySof IQ Vivity® IOL3

        Defocus Range

        6-Month Binocular Distance Corrected Visual Acuity3*

        Defocus curve graph showing that the defocus range for AcrySof IQ Vivity® is comparable to that of AcrySof® IQ monofocal. A portion of the graph is highlighted showing that Vivity® patients can achieve 20/20 (0 logMAR) visual acuity even with a refractive miss of ±0.5 diopters.
        A refractive miss of +/- 0.5D can still leave a patient with VA of 20/20

        *Data obtained from a prospective, randomised, controlled study of bilateral implantation of 106 AcrySof IQ Vivity® patients and 111 AcrySof® IQ monofocal IOL patients from a computerised visual acuity test system.

        Range Of Vision

        6-Month Binocular Distance Corrected Visual Acuity3*

        Defocus curve graph showing that the defocus range for AcrySof IQ Vivity® is comparable to that of AcrySof® IQ monofocal. A portion of the graph is highlighted, showing that Vivity® allows patients to experience a continuous range of vision from distance to as close as 50 cm
        AcrySof IQ Vivity® IOL patients experience a continuous extended range of vision from distance to as close as 50 cm

        Clinical Support

        Kohnen T, et al. The novel optical design and clinical classification of a wavefront-shaping presbyopia-correcting intraocular lens.

         

        Evaluating the clinical rationale of wavefront-shaping technology, describing how intraocular lenses (IOLs) using wavefront-shaping technology are differentiated from refractive or diffractive optical presbyopia-correcting designs, and describing the mode of action of this technology.

        Baur I, et al. Unilateral implantation of a new non-diffractive extended range-of-vision IOL in a young patient with Curschmann-Steinert myotonic dystrophy

         

        Case study of a 36-year old Curschmann-Steinert myotonic dystrophy patient with posterior subcapsular cataract treated with unilateral implantation of an extended depth of focus intraocular lens

        Arrigo A, et al. Extended depth-of-focus (EDOF) AcrySof IQ Vivity® intraocular lens implant: a real-life experience

         

        Reported real-life experience related to the implant of EDOF AcrySof IQ Vivity® (Alcon Inc., USA) IOL

        Bala C, et al. Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens

         

        Evaluating the effectiveness and safety of a novel presbyopia-correcting intraocular lens (IOL) with a nondiffractive design, DFT015, compared with an aspheric monofocal IOL, SN60WF.
        NOTE: Available to JCRS subscribers and ACSRS / ESCRS members

        Technical Specifications1,10

        technical specifications and comparison graph for vivity

        Instructions for Use (IFU)

         

        For a full list of indications, contraindications and warnings, please visit ifu.alcon.com and refer to the relevant product’s instructions for use.

        Visit IFU Database

        Alcon Experience Academy

         

        For relevant training content from industry thought leaders

        Visit AEA Portal

        References:
        1. Acrysof IQ Vivity® Extended Vision IOL Global Directions for Use.

        2. Alcon Data on File, 2018.

        3. Bala C, et al. Multi-country clinical outcomes of a new non-diffractive presbyopia-correcting IOL. J Cataract Refract Surg. 2021; DOI:10.1097/j.jcrs.0000000000000712.

        4. McCabe C, Berdahl J, Reiser H, et al. Clinical outcomes in a U.S. registration study of a new EDOF intraocular lens with a non-diffractive design. J Cataract Refract Surg. 2022;48(11):1297-1304.doi:10.1097/j. jcrs.0000000000000978.

        5. Baur I, et al. Visualization of ray propagation through extended depth-of-focus intraocular lenses. Diagnostics 2022, 12, 2667. https://doi.org/10.3390/diagnostics12112667.

        6. Ligabue E, et al. ACRYSOF IQ VIVITY: Natural vision at a range of distances provided by a novel optical technology. Cataract & Refractive Surgery Today. April 2020 //

        7. Lawless M. Insighnews. "An IOL to change the cataract surgery paradigm?" available at "https://www.insightnews.com.au/an-iol-to-change-the-cataract-surgery-paradigm/". Accessed Date 17.07.2020.

        8. Ike K. Ahmed, et al. The Vivity Extended Depth of Focus IOL: Our Clinical Experience. Cataract & Refractive Surgery Today. February 2021//

        9. Kohnen T, et al. The Novel Optical Design and Clinical Classification of a Wavefront-Shaping Presbyopia-Correcting Intraocular Lens. Clinical Ophthalmology. 2023:17 2449–2457.

        10. AcrySof IQ Vivity® Toric Extended Vision IOL Directions for Use.

        11. Braga-Mele R, et al. Multifocal intraocular lenses: relative indications and contraindications for implantation. J Cataract Refract Surg. 2014;40(2):313-322.

        12. Gundersen KG, et al. Retreatments after multifocal intraocular lens implantation: an analysis. Clin Ophthalmol. 2016:10;365–371.

        13. Zvornicanin J, et al. Premium intraocular lenses: The past, present and future. J Curr Ophthalmol. 2018;30(4):287-296.

         

        For indications, contraindications and warnings, please refer to the relevant product's instruction for use.

        ©2024 Alcon Laboratories Pty Ltd. AUS: 18 00 224 15 3; Auckland NZ: 08 00 1 01 1 06. ANZ-VIV-2400001
        Australia
        Alcon See Briliantly